8-K: Cytokinetics' Aficamten Outperforms Metoprolol in HCM Trial

Cytokinetics announced positive primary results from its MAPLE-HCM Phase 3 trial, demonstrating aficamten's superiority over metoprolol in treating obstructive hypertrophic cardiomyopathy.

Summary

• Primary results from the MAPLE-HCM Phase 3 clinical trial for aficamten were presented in a Hot Line Session at the European Society of Cardiology Congress 2025 and simultaneously published in The New England Journal of Medicine.
• The trial was a randomized, double-blind, active-comparator study of aficamten compared to metoprolol as monotherapy in 175 patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
• Aficamten demonstrated statistically significant superiority over metoprolol on the primary endpoint of mean change from baseline in peak oxygen uptake (pVO2) after 24 weeks.
• The least-squares mean (LSM) difference between groups for pVO2 was 2.3 mL/kg/min (95% CI 1.5 to 3.1; p<0.0001), with aficamten showing an increase of +1.1 mL/kg/min and metoprolol a decrease of -1.2 mL/kg/min.
• Aficamten also showed superiority in five of six secondary endpoints, including improvements in NYHA Functional Class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), NT-proBNP, and left ventricular outflow tract (LVOT) gradients.
• The overall rate of adverse events was similar between groups, but aficamten had a significantly lower rate of down-titration due to adverse events compared to metoprolol (4.5% vs. 29.9%).

Sentiment

Score: 9

Explanation: The trial results are overwhelmingly positive, demonstrating clear superiority over the long-standing standard of care across multiple clinically relevant endpoints, with a generally favorable safety profile. This significantly de-risks the regulatory approval process and enhances commercial prospects for aficamten.

Positives

• Aficamten demonstrated statistically significant superiority over metoprolol in improving exercise capacity, with a least-squares mean difference of 2.3 mL/kg/min (p<0.0001) in pVO2.
• 51% of patients on aficamten showed an improvement of one or more NYHA functional class, compared to 26% on metoprolol (p<0.001).
• Significant improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) with an LSM difference of 6.9 points (p<0.01).
• Aficamten led to an 81% reduction in NT-proBNP, a biomarker of cardiac wall stress (p<0.0001).
• Significant improvements in resting LVOT-G (LSM difference = -30 mmHg; p<0.0001) and Valsalva LVOT-G (LSM difference = -35 mmHg; p<0.0001).
• Significant improvement in left atrial volume index (LAVI) (LSM difference = 7.0 ml/m2; p<0.0001), consistent with improved diastolic dysfunction and suggesting potentially favorable cardiac remodeling.
• Aficamten was down-titrated in only 4.5% of patients, significantly less than metoprolol (29.9%), indicating better tolerability for some side effects.
• The positive results were consistent across all prespecified subgroups, including newly diagnosed or treatment-naive patients, and in patients with less severe oHCM than previously studied in SEQUOIA-HCM.

Negatives

• One patient receiving aficamten, a 69-year-old woman with multiple co-morbidities, developed a viral illness and subsequently died.
• Aficamten was associated with a modest reduction in left ventricular ejection fraction (LVEF) (LSM difference = -4%; p<0.0001), with 1.1% of patients experiencing LVEF <50% per core laboratory.
• Hypertension was reported in 10.2% of aficamten patients, compared to 2.3% on metoprolol, making it the most common adverse event reported in excess of the comparator.
• No significant difference was observed between aficamten and metoprolol on the secondary endpoint of left ventricular mass index (LVMI) (p=0.16).

Risks

• Aficamten is an investigational drug candidate and is not yet approved by any regulatory agency; its safety and efficacy have not been fully established.
• The modest reduction in LVEF observed with aficamten, though generally managed, requires careful monitoring as LVEF <50% led to down-titration in some patients.
• Potential for adverse events such as hypertension, which was more common in aficamten-treated patients than in metoprolol-treated patients.
• Forward-looking statements are subject to various risks and uncertainties, including those related to Cytokinetics' business outlined in its SEC filings, which could cause actual results to differ materially.

Future Outlook

Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, with an FDA PDUFA target action date of December 26, 2025. The company is also evaluating aficamten in additional clinical trials for obstructive and non-obstructive HCM (ACACIA-HCM, CEDAR-HCM, FOREST-HCM), and developing other drug candidates for heart failure and muscular dystrophy.

Management Comments

• "This important study has the potential to inform our approach to treating obstructive HCM, as MAPLE-HCM provides the field its first look at a cardiac myosin inhibitor compared directly to a beta-blocker." Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Hospital Universitario Puerta de Hierro.
• "In showing that aficamten is superior to metoprolol on all clinically relevant efficacy endpoints, these results call into question the reliance on beta-blockers as the initial treatment modality for obstructive HCM that has prevailed for over 60 years." Pablo Garcia-Pavia, M.D., Ph.D.
• "These results demonstrate that aficamten meaningfully improves exercise capacity in patients with obstructive HCM while treatment with metoprolol resulted in a meaningful reduction in exercise capacity." Fady I. Malik, M.D., Ph.D., Cytokinetics Executive Vice President of Research & Development.
• "The clinical difference in the two treatments is reinforced by the effect of aficamten on the secondary endpoints. Compared to first-line standard-of-care metoprolol, treatment with aficamten had a larger effect on measures of symptoms, functional class, and LVOT gradients." Fady I. Malik, M.D., Ph.D.

Industry Context

The positive results for aficamten against metoprolol, a long-standing standard-of-care beta-blocker for over 60 years, represent a significant potential shift in the treatment paradigm for obstructive hypertrophic cardiomyopathy. This positions aficamten as a strong contender to become a new first-line treatment, potentially disrupting the market dominated by traditional therapies and offering a more effective option for patients. The data also expands the potential patient population to include those with less severe disease, broadening market reach.

Comparison to Industry Standards

• Aficamten demonstrated superiority to metoprolol, which has been the standard-of-care beta-blocker for obstructive HCM for over 60 years, challenging the prevailing initial treatment modality.
• The MAPLE-HCM trial included patients with less severe oHCM and higher predicted peak oxygen uptake (pVO2) compared to the pivotal SEQUOIA-HCM trial, broadening the potential patient population for aficamten beyond previously studied cohorts.
• Unlike metoprolol, which resulted in a meaningful reduction in exercise capacity, aficamten meaningfully improved it, highlighting a significant clinical advantage over the established therapy.
• Aficamten's effect on symptoms, functional class, and LVOT gradients was larger compared to metoprolol, indicating a more comprehensive therapeutic benefit than the current first-line standard-of-care.

Stakeholder Impact

• Shareholders: Highly positive impact due to strong clinical trial results, increasing the likelihood of regulatory approval and successful commercialization, potentially leading to significant revenue growth and increased share value.
• Patients with oHCM: Significant positive impact as aficamten offers a potentially superior and more effective treatment option compared to current standard-of-care beta-blockers, improving exercise capacity, symptoms, and cardiac function.
• Healthcare Providers: Provides a new, potentially first-line therapeutic option for managing obstructive hypertrophic cardiomyopathy, challenging existing treatment protocols and offering a more effective tool.
• Competitors: Puts pressure on developers of other HCM treatments and existing standard-of-care providers due to aficamten's demonstrated superiority, potentially shifting market dynamics.

Next Steps

• Continued regulatory review of the New Drug Application (NDA) for aficamten by the FDA, with a PDUFA target action date of December 26, 2025.
• Continued regulatory review of the Marketing Authorization Application (MAA) for aficamten by the European Medicines Agency (EMA).
• Continued regulatory review of the NDA for aficamten by The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) with Priority Review.
• Further evaluation of aficamten in ACACIA-HCM (non-obstructive HCM), CEDAR-HCM (pediatric oHCM), and FOREST-HCM (open-label extension) clinical trials.
• Cytokinetics will host an investor webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the MAPLE-HCM results and other data presented at the European Society of Cardiology Congress 2025.

Key Dates

Recommendation

The overwhelmingly positive Phase 3 MAPLE-HCM trial results demonstrate aficamten's clear superiority over metoprolol, the long-standing standard of care for obstructive hypertrophic cardiomyopathy, across multiple primary and secondary endpoints. This significantly de-risks the upcoming FDA PDUFA date of December 26, 2025, and positions aficamten as a potential new first-line therapy. The broad applicability to patients with less severe disease, coupled with a generally favorable safety profile compared to metoprolol, suggests a substantial market opportunity. Given the strong clinical data and imminent regulatory decision, the stock is poised for significant upside.

Keywords

Aficamten, Hypertrophic Cardiomyopathy, oHCM, MAPLE-HCM, Clinical Trial, Cardiac Myosin Inhibitor, Cytokinetics, Metoprolol, FDA, PDUFA, Cardiology